A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma
Latest Information Update: 19 Aug 2024
At a glance
- Drugs APG-157 (Primary) ; Bevacizumab
- Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Therapeutic Use
- Sponsors Aveta Biomics
Most Recent Events
- 12 Dec 2023 Status changed from not yet recruiting to recruiting.
- 28 Aug 2023 New trial record